Eli Lilly And Co (LLY) Shares Bought by First Citizens Bank & Trust Co.

Share on StockTwits

First Citizens Bank & Trust Co. boosted its position in shares of Eli Lilly And Co (NYSE:LLY) by 21.6% in the first quarter, Holdings Channel reports. The fund owned 12,878 shares of the company’s stock after acquiring an additional 2,284 shares during the period. First Citizens Bank & Trust Co.’s holdings in Eli Lilly And Co were worth $1,671,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also recently added to or reduced their stakes in LLY. Bank of New York Mellon Corp raised its position in shares of Eli Lilly And Co by 0.3% during the third quarter. Bank of New York Mellon Corp now owns 9,501,142 shares of the company’s stock valued at $1,019,568,000 after buying an additional 27,009 shares during the last quarter. Caxton Associates LP acquired a new position in shares of Eli Lilly And Co during the third quarter valued at about $250,000. Mutual Advisors LLC raised its position in shares of Eli Lilly And Co by 36.9% during the third quarter. Mutual Advisors LLC now owns 9,038 shares of the company’s stock valued at $970,000 after buying an additional 2,438 shares during the last quarter. Mackenzie Financial Corp raised its position in shares of Eli Lilly And Co by 23.1% during the third quarter. Mackenzie Financial Corp now owns 53,850 shares of the company’s stock valued at $5,779,000 after buying an additional 10,109 shares during the last quarter. Finally, HPM Partners LLC raised its position in shares of Eli Lilly And Co by 8.3% during the third quarter. HPM Partners LLC now owns 7,170 shares of the company’s stock valued at $769,000 after buying an additional 549 shares during the last quarter. 79.58% of the stock is owned by hedge funds and other institutional investors.

NYSE LLY opened at $124.08 on Tuesday. The stock has a market capitalization of $127.47 billion, a P/E ratio of 22.36, a price-to-earnings-growth ratio of 2.33 and a beta of 0.33. Eli Lilly And Co has a twelve month low of $77.09 and a twelve month high of $132.13. The company has a current ratio of 1.73, a quick ratio of 1.38 and a debt-to-equity ratio of 1.07.

Eli Lilly And Co (NYSE:LLY) last posted its earnings results on Wednesday, February 6th. The company reported $1.33 earnings per share for the quarter, missing the Zacks’ consensus estimate of $1.36 by ($0.03). The business had revenue of $6.44 billion during the quarter, compared to the consensus estimate of $6.28 billion. Eli Lilly And Co had a net margin of 13.16% and a return on equity of 44.66%. The business’s revenue was up 4.5% compared to the same quarter last year. During the same period in the previous year, the firm earned $1.14 EPS. As a group, research analysts anticipate that Eli Lilly And Co will post 5.66 earnings per share for the current fiscal year.

A number of research analysts have recently commented on LLY shares. UBS Group cut their price objective on shares of Eli Lilly And Co from $107.53 to $100.00 and set an “average” rating for the company in a research report on Friday, February 8th. Argus reaffirmed a “buy” rating on shares of Eli Lilly And Co in a research report on Thursday, December 27th. Zacks Investment Research raised shares of Eli Lilly And Co from a “hold” rating to a “buy” rating and set a $121.00 price objective for the company in a research report on Wednesday, December 19th. BMO Capital Markets reaffirmed a “buy” rating on shares of Eli Lilly And Co in a research report on Wednesday, December 19th. Finally, Cantor Fitzgerald reaffirmed a “buy” rating on shares of Eli Lilly And Co in a research report on Monday, February 4th. Ten investment analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company. Eli Lilly And Co has an average rating of “Buy” and a consensus price target of $118.02.

In other Eli Lilly And Co news, insider Donald A. Zakrowski sold 1,000 shares of the company’s stock in a transaction dated Friday, March 1st. The shares were sold at an average price of $127.01, for a total transaction of $127,010.00. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, major shareholder Lilly Endowment Inc sold 136,577 shares of the company’s stock in a transaction dated Thursday, January 17th. The stock was sold at an average price of $118.33, for a total transaction of $16,161,156.41. Following the sale, the insider now directly owns 117,866,748 shares in the company, valued at $13,947,172,290.84. The disclosure for this sale can be found here. Insiders have sold 989,224 shares of company stock worth $123,587,253 over the last ninety days. Insiders own 0.11% of the company’s stock.

TRADEMARK VIOLATION WARNING: This report was posted by Macon Daily and is the property of of Macon Daily. If you are reading this report on another site, it was copied illegally and republished in violation of United States & international copyright and trademark law. The original version of this report can be viewed at https://macondaily.com/2019/04/16/eli-lilly-and-co-lly-shares-bought-by-first-citizens-bank-trust-co.html.

Eli Lilly And Co Company Profile

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates through two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.

Recommended Story: What is a Buy-Side Analyst?

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly And Co (NYSE:LLY).

Institutional Ownership by Quarter for Eli Lilly And Co (NYSE:LLY)

Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.